PRIMARY STUDY
The Effect of Palmitoylethanolamide on Pain Intensity, Central and Peripheral Sensitization, and Pain Modulation in Healthy Volunteers-A Randomized, Double-Blinded, Placebo-Controlled Crossover Trial
Key Findings: This study finds that palmitoylethanolamide (PEA) has clinically significant pain-relieving properties and acts centrally and peripherally to produce pain relief
Type of Study: Double Blind Clinical Trial
Study Sample Size: 14
Study Result: Positive
Research Location(s): Austria
Year of Pub: 2022
Cannabinoids Studied: Anandamide (AEA), Palmitoylethanolamide (PEA)
Phytocannabinoid Source: Not Applicable
Receptors Studied: CB2, TRPV1, PPAR - Alpha
DOSING DETAILS 
Study Dosing Objective: Effective Dose
Established Protocol: Effective dose
Route of Administration: Oral (Ingestion)
Dosage Form: tablets
Dosing Regimen: PEA 400mg three times daily
Treatment Duration: 28 days
Citation: Lang-Illievich K, et al. The Effect of Palmitoylethanolamide on Pain Intensity, Central and Peripheral Sensitization, and Pain Modulation in Healthy Volunteers-A Randomized, Double-Blinded, Placebo-Controlled Crossover Trial. Nutrients. 2022; 14:(unknown pages). doi: 10.3390/nu14194084
Authors: Lang-Illievich K, Klivinyi C, Rumpold-Seitlinger G, Dorn C, Bornemann-Cimenti H
